Yeast-derived postbiotic fermentate (EpiCor®) modulates inflammatory cytokines in healthy adults: double-blind crossover trial
A single 500-mg dose of EpiCor® selectively reduced pro-inflammatory cytokines and transiently redistributed immune cell subsets within hours of ingestion in healthy adults.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
The abstract reports significant reductions in IFN-γ and IL-1ra at 1 hour and in IL-4, IL-7, and IL-8 at 2 hours post-ingestion versus placebo. A transient decrease in circulating CD25⁺ immune cell subsets was also observed. The abstract is truncated, precluding full assessment of 2- and 3-hour outcomes.
How it was done
Randomized, double-blind, placebo-controlled acute crossover trial in 30 healthy adults. Participants received a single 500-mg dose of EpiCor® or placebo on two clinic visits separated by a 1-week washout; blood drawn at 0, 1, 2, and 3 hours.
Risk of bias
The abstract is incomplete, cutting off mid-results; full data on 2- and 3-hour timepoints are unavailable. The sample size is small (n=30), the context is acute and in healthy individuals, limiting any clinical extrapolation.
What this study does NOT prove
This study does not prove that EpiCor® prevents, treats, or reduces risk of any inflammatory or infectious condition.
In clinical practice
No clinical recommendation is warranted from a single acute trial in healthy adults with an incomplete abstract. The clinical relevance of the observed cytokine shifts cannot be determined without the full text.
Limitations
The abstract is incomplete, cutting off mid-results; full data on 2- and 3-hour timepoints are unavailable. The sample size is small (n=30), the context is acute and in healthy individuals, limiting any clinical extrapolation.
Technical appendix
Version history
- 1.0 · 2026-08-24 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.